Dyadic International Reports Q1 2025 Financial Results

Dyadic International Inc. ( (DYAI) ) has released its Q1 earnings. Here is a breakdown of the information Dyadic International Inc. presented to its investors.

Dyadic International, Inc. is a biotechnology company specializing in the development of functional recombinant solutions and proprietary production strains for large-scale protein and enzyme manufacturing, catering to life science, nutrition, and industrial applications.

In its first quarter of 2025, Dyadic International reported significant progress in its commercialization efforts, particularly with its proprietary Dapibus™ and C1 microbial protein production platforms. The company highlighted its strategic focus on developing scalable products with recurring revenue potential, supported by partnerships with organizations like CEPI and the Gates Foundation.

Key financial metrics for the quarter showed an increase in revenue to approximately $394,000, driven by grant revenues from CEPI and the Gates Foundation, although offset by a decrease in research and development revenue. The company reported a net loss of $2,028,000, slightly higher than the previous year, attributed to increased costs and decreased other income. Dyadic’s cash position stood at $7.4 million as of March 31, 2025.

Strategically, Dyadic is advancing its portfolio with new life science products, aiming for a Q3 2025 commercial launch of its Human Serum Albumin in collaboration with Proliant Health and Biologicals. The company is also exploring non-animal dairy applications and expanding its nucleic acid enzymes portfolio.

Looking ahead, Dyadic’s management remains optimistic about expanding the reach of its platforms and driving innovation through strategic partnerships and non-dilutive funding. The company aims to broaden global access to affordable biologics, proteins, and enzymes, providing a stable foundation for long-term shareholder value.